SC
SABS icon

Stempoint Capital’s SAB Biotherapeutics SABS Stock Holding History

Stempoint Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
342,631
-32,369
-9% -$120K 0.23% 68
2026
Q1 		$1.44M Buy
375,000
+228,442
+156% +$911K 0.28% 59
2025
Q4 		$548K Buy
+146,558
New +$482K 0.09% 71

Other funds holding SABS

Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stempoint Capital's SABS Position: Q2 2026 in Review

Stempoint Capital reduced its SAB Biotherapeutics (SABS) stake by 8.6% in Q2 2026, selling an estimated $120K and leaving 342,631 shares worth $1.34M. The position accounts for 0.23% of the portfolio, ranked #68.

Stempoint Capital first reported a position in SABS in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.44M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Stempoint Capital held 342,631 shares of SAB Biotherapeutics worth $1.34M as of Q2 2026.
  • Stempoint Capital sold 32,369 SAB Biotherapeutics shares in Q2 2026, an estimated $120K.
  • SAB Biotherapeutics made up 0.23% of Stempoint Capital's portfolio in Q2 2026, its #68 holding.
  • Stempoint Capital first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Stempoint Capital's SAB Biotherapeutics position peaked at $1.44M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.